Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 17/20 | 0.66 |
| ▸ | RARG | P13631 | 15/20 | 0.66 |
| ▸ | RARA | P10276 | 15/20 | 0.66 |
| ▸ | RXRA | P19793 | 1/20 | 0.54 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6237361 | 0.87 | RARB (0.78) | RARBRARGRARARXRANR2E1 | |
| SCHEMBL4505397 | 0.86 | RARB (0.70) | RARBRARGRARARXRANR2E1 | |
| SCHEMBL6238148 | 0.84 | RARB (0.77) | RARBRARGRARARXRANR2E1 | |
| SCHEMBL4503989 | 0.83 | RARB (0.66) | RARBRARGRARARXRANR2E1 | |
| SCHEMBL4499262 | 0.82 | RARB (0.65) | RARBRARGRARARXRANR2E1 | |
| SCHEMBL5707360 | 0.81 | RARB (0.50) | RARBRARGRARARXRANR2E1 | |
| SCHEMBL13785038 | 0.79 | RARB (0.77) | RARBRARGRARARXRANR2E1 | |
| SCHEMBL8706311 | 0.79 | RARB (1.00) | RARBRARGRARARXRANR2E1 | |
| SCHEMBL5326691 | 0.79 | RARB (0.69) | RARBRARGRARARXRANR2E1 | |
| SCHEMBL8771650 | 0.79 | RARB (0.77) | RARBRARGRARARXRANR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020156054-A1 | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities | ALLERGAN, INC. | 2002-10-24 | — | — | US | disclosed |
| EP-0991636-A1 | SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES | Allergan Sales, Inc. (US) | 2000-04-12 | — | — | EP | disclosed |
| WO-1998058922-A1 | SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES | ALLERGAN SALES, INC. (US) | 1998-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156054-A1 | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities | RXRA, RARA, RXRG | RARB 7/4885RARG 4/4885RARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.